SEC Form 4

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add Ingargiola I	•	ing Person <sup>*</sup>				lame <b>and</b> Ticker o Rx Inc. [BIC		g Syml	bol				tionship of F all applicat Director		Person(s)	) to Issuer 10% Ov	vner
(Last)	(First)	,	iddle)		3. Date of 12/30/20	Earliest Transaction 22	on (Montł	n/Day/	Year)				Officer (g below)	give title		Other (s below)	specify
2390 EAST OF SUITE 500	RANGEW	OOD AVENUE			4. If Amen	dment, Date of Or	iginal File	ed (Mo	onth/Day/Ye	ear)		6. Indiv X		d by One I	Reporting	g Person	ŕ
(Street) ANAHEIM	FL	34	683										Form file	d by More	than On	e Reportin	g Person
(City)	(State)	(Zi	p)														
		Та	ble I - Nor	n-Deri	ivative Se	ecurities Acq	uired, I	Disp	osed of,	, or l	Benefic	ially Ow	ned				
1. Title of Securit	ty (Instr. 3)			Date	isaction n/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securit Disposed				5. Amount Securities Beneficial Following	ly Owned Reported	6. Owne Form: D or Indir (Instr. 4	Direct (D) rect (I)	7. Nature of Indirect Beneficial Ownership
							Code	v	Amount		(A) or (D)	Price	Transactio (Instr. 3 an				(Instr. 4)
Common Stock	, par value	\$0.001		12/3	30/2022		<b>A</b> <sup>(1)</sup>		5,319	9	Α	\$ <mark>0</mark>	33,	675	]	D	
						urities Acquii s, warrants, c							əd				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/)	ate, 1	4. Fransaction Code (Instr. 3)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date I Expirati (Month/	on Dat		Secu Deri	tle and An urities Und vative Sec tr. 3 and 4)	derlying curity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e C s F lly D o j (l	0. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## Explanation of Responses:

1. These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to \$5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was \$0.94.

Date

Exercisable

(D)

Expiration

Title

Date

## Remarks:

/s/ Luisa Ingargiola
----------------------

\*\* Signature of Reporting Person

Amount

Number

of Shares

01/09/2023

Transaction(s)

(Instr. 4)

rson I

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Code V (A)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.